Lipid Changes in the 2NN Trial
Lipid Changes in the 2NN Trial
Teresa García-Benayas
NULL
*Correspondence: Teresa García-Benayas, Email not available
Abstract
Dyslipidemia is an important clinical problemin HIV-infected patients, particularly when theyare receiving protease inhibitor (PI)-containingregimens. Switching to non-nucleoside analogues(NNA) has been attempted and differentstudies have demonstrated clear, but not identical,benefits with both efavirenz (EFV) andnevirapine (NVP).
